Nasopharyngeal carcinoma
Conditions
Interventions
Control group:None
Sponsors
Affiliated hangzhou first people's hospital, zhejiang university school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Disease Diagnosis: Experimental Group (NPC group): Patients pathologically diagnosed with primary nasopharyngeal carcinoma. Control Group (Normal group): Adjacent normal tissue: Taken from distant areas of the same nasopharyngeal carcinoma patient (usually >1 cm from the tumor margin) and pathologically confirmed as normal or inflammatory (e.g., chronic nasopharyngitis) nasopharyngeal mucosa. (This represents the ideal scenario for a paired sample design). Independent normal/benign lesion tissue: Tissue taken from patients undergoing biopsy or surgery for benign lesions such as chronic nasopharyngitis; 2. Sample Availability and Quality: Sufficient amounts of fresh frozen tissue are available (for RNA extraction, qPCR) and/or formalin-fixed paraffin-embedded tissue (for IHC, DNA extraction); 3. Samples have complete clinicopathological information (such as TNM staging, histological type, etc.).
Exclusion criteria
Exclusion criteria: 1. Treatment history interference: Exclude patients who have received any antitumor treatment (including radiotherapy, chemotherapy, immunotherapy, or targeted therapy) before sample collection, in order to prevent treatments from altering gene expression and the microenvironment; 2.Mixed pathological interference: Exclude patients with concurrent other malignant tumors or non-cancerous nasopharyngeal space-occupying lesions (such as lymphoma); 3. Poor sample quality: Postoperative tissues were not rapidly frozen or promptly fixed, leading to severe RNA degradation (e.g., RNA integrity number RIN<6.5). Tumor cell content in paraffin sections is too low (e.g., <70%), or normal tissues are contaminated by tumor cells; 4.Incomplete information: cases with severely missing clinical pathological data or follow-up information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pathological classification; | — |
Countries
China
Contacts
Public ContactJing Li
Affiliated hangzhou first people's hospital, zhejiang university school of medicine
Outcome results
None listed